Retatrutide side effects: what the trials show and how to manage them

Jump to: Side effects by dose | Stomach and gut side effects | Heart rate and irregular heartbeats | Dysesthesia: skin sensation changes | Muscle loss during rapid weight loss | Mental health and mood | Drug interactions and contraception | Other side effects | How retatrutide compares to Mounjaro and Wegovy | Discontinuation and weight regain | What we don’t yet know | When to speak to a healthcare professional | FAQ | Take home message | Second Nature’s Mounjaro programme | References

Retatrutide’s side effects fall into three main groups: stomach and gut symptoms during dose increases, a heart-rate increase larger than other GLP-1 medications, and a skin sensation called dysesthesia that emerged at higher doses in Phase 3 trials.

Most side effects seem to resolve with slower dose increases and clinical supervision, but the long-term safety picture remains incomplete.^1,2

Retatrutide isn’t legally available in the UK as of May 2026. If you’re researching its side effects, this guide covers what the trials show dose by dose, what each finding means, what isn’t yet known, and when to speak to a doctor.

Side effects by dose

Retatrutide’s side-effect profile varies significantly with dose.

The 1 mg starting dose looks similar to Mounjaro at 2.5 mg, mild and mostly tolerable.

The 12 mg target dose, where most of the weight loss occurs, is associated with more frequent and more varied side effects.^1,2

Most side effects are mild to moderate, appear during the period when the dose is increased (titration), and resolve over four to six weeks once the body adjusts.¹

Lilly’s Phase 2 trial found that starting at 2 mg rather than 4 mg reduced nausea and vomiting during the stepping-up phase, which is why every Phase 3 trial uses a slow stepwise dose schedule.^1,2

The dose-by-dose data from the published trials:

TRIUMPH-4’s 18.2% discontinuation rate at 12 mg is more than three times higher than TRANSCEND-T2D-1’s 5.1% on the same dose.

Lilly reported that some TRIUMPH-4 dropouts were people losing more weight than they wanted, rather than people stopping due to side effects.

The populations also differed: TRIUMPH-4 enrolled adults living with obesity and knee osteoarthritis over 68 weeks, while TRANSCEND-T2D-1 enrolled people living with type 2 diabetes over 40 weeks.

Stomach and gut side effects

Stomach and gut symptoms are the most common reason people stop or struggle with retatrutide.

They follow a predictable pattern across the trials, and slow dose increases are the most reliable way to reduce them.^1,2

Why these symptoms happen

Retatrutide works by mimicking three hormones: GLP-1, GIP, and glucagon.

The GLP-1 part slows how quickly food leaves the stomach (technically called gastric emptying) by 30 to 40%, and signals fullness to the brain.¹

Food sits in the stomach longer than usual, which can feel like nausea, bloating, or reflux. As the gut adjusts, symptoms typically resolve.¹

Timeline

Most stomach and gut symptoms appear in the first one to two weeks after a dose increase, then settle over four to six weeks. They tend to spike again with each dose increase.¹

Once you’re stable on a maintenance dose, symptoms usually become much less frequent.^1,2

Practical ways to manage side effects

• Eat smaller meals
• Eat slowly and mindfully
• Stop when you feel full, not when the plate is empty
• Avoid meals higher in fat in the two hours after your injection
• Include lean protein at each meal (chicken, fish, beans, eggs, tofu, Greek yoghurt)
• Stay hydrated and sip water throughout the day
• Don’t lie down after meals; opt for a short walk instead
• If you’re constipated, eat a wide variety of fibre sources (wholegrains, beans, lentils, fruits, vegetables, nuts, seeds)
• Inject in the evening if nausea is affecting your day
• If you’ve been vomiting for more than 24 hours, contact your clinician
• Speak to your doctor or prescribing physician if symptoms persist or become too uncomfortable

If symptoms haven’t settled after several weeks at a stable dose, they may not settle on their own so it’s best to speak with your prescribing clinician or pharmacist.¹

Heart rate and irregular heartbeats

^{Retatrutide’s effects on the heart are part of its safety profile that clinicians and regulators are watching most closely.1,2}

They’re also one of the main reasons regulators want full long-term data before the drug is widely used.

Heart rate

The Phase 2 trial showed a dose-related increase in resting heart rate. At 12 mg, the average increase was around 6.7 beats per minute, peaking around week 24 and declining toward baseline by weeks 36 to 48.¹

This increase in heart rate is higher than what’s been reported for Mounjaro (around 2 to 4 bpm) or Wegovy (around 1 to 4 bpm).⁴

The likely reason is the glucagon part of retatrutide. The glucagon receptor raises the body’s resting energy use, which tends to raise heart rate.¹

Irregular heartbeats

Across Phase 2 and Phase 3 trials, irregular heartbeats were reported in 2 to 11% of people on retatrutide, compared with around 2% on placebo.^1,2

None were classified as serious, and there’s been no increase in serious cardiac events like heart attack, stroke, or cardiovascular death.^1,2

The rate is low in absolute terms, none of the irregular heartbeats was severe, and the absence of serious problems so far is reassuring at this stage.

What this means in practice

If you have a known heart-rhythm condition, uncontrolled high blood pressure, or a recent cardiac event, retatrutide isn’t a medication to take outside of a clinician’s care. Your GP or specialist would consider this part of the overall picture.¹

For most people without pre-existing heart disease, the heart-rate increase is unlikely to cause symptoms.¹

There’s no dedicated cardiovascular outcomes trial for retatrutide yet. One is part of Lilly’s broader development plan but won’t read out for years.²

When to seek advice

If you notice palpitations, a sustained racing heart, dizziness, or chest discomfort while on retatrutide, contact your GP.

These symptoms aren’t always retatrutide-related, but they need a clinical assessment.

Dysesthesia: skin sensation changes

Dysesthesia is an altered sense of touch. The term wasn’t widely discussed before TRIUMPH-4 reported in December 2025.²

It wasn’t seen in the Phase 2 trial, so its appearance at higher Phase 3 doses raised questions about what was driving it.^1,2

What it feels like

People describe dysesthesia as burning, tingling, prickling, or a feeling of skin being unusually sensitive to clothing, water, or pressure.²

It’s not pain caused by injury, and it isn’t an allergic reaction. Sensations that should feel neutral feel uncomfortable or strange.

How often it happens

The rates vary by trial and population:^2,3

• TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo
• TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo
• Phase 2 trial (Jastreboff 2023): not reported

The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1.

Possible reasons include the longer treatment duration in TRIUMPH-4 (68 vs 40 weeks), differences in how symptoms were captured, and differences in patient populations.^2,3

Lilly has said most cases were mild and most resolved while people continued treatment.²

Why it might happen

Why dysesthesia happens isn’t yet confirmed. The leading hypothesis is that the glucagon component is involved, since GLP-1/GIP-only drugs like Mounjaro haven’t reported it at similar rates.²

But Wegovy’s new 7.2 mg dose has now flagged similar skin sensations, suggesting this may partly be a wider effect across GLP-1 medications at higher doses.⁴

When to flag it

If you experience persistent burning, tingling, or unusual skin sensitivity that doesn’t settle, speak to your clinician.

Most cases in the trials were mild and resolved without stopping the medication, but it’s not something to ignore, particularly if it’s affecting sleep or daily life.

Muscle loss during weight loss

When people lose weight on a GLP-1 medication, a portion of the weight loss comes from lean tissue, including muscle.

Research on the Mounjaro and retatrutide trials suggests this typically accounts for around a quarter of total weight loss, similar to what’s observed with other forms of significant weight reduction.

Our muscles play a central role in regulating blood sugar levels. They also support our day-to-day strength and mobility, which becomes more important as we age.

The two factors most strongly associated with preserving muscle mass during weight loss are adequate protein intake and resistance training.

Research on adults losing weight suggests a protein intake of 1.2 to 1.6 grams per kg of body weight per day.

For someone weighing 90 kg, this amounts to around 110-145 grams of protein daily, or a portion of protein the size of the palm of your hand in your meals.

Reaching this level of protein intake can be challenging when taking a GLP-1 medication, as these medications reduce appetite.

Including a protein source at each meal helps spread intake across the day. Common sources include eggs, Greek yoghurt, chicken, fish, tofu, lentils, beans, and cottage cheese.

Resistance training is any exercise that works the muscles against weight or resistance. This includes bodyweight exercises (squats, lunges, press-ups), resistance bands, dumbbells, and weight machines.

Research suggests that even short sessions a couple of times a week can help to maintain muscle mass during weight loss.

Mental health and mood

GLP-1 medications have been under regulatory review for possible links to suicidal thoughts and mood changes.

The European Medicines Agency reviewed semaglutide and liraglutide in 2023 and 2024 and concluded that the available evidence didn’t support a causal link with suicidal ideation.

The FDA reached similar conclusions for tirzepatide and semaglutide.

Retatrutide’s Phase 2 and Phase 3 trials haven’t reported a mood-related concern.

The TRIUMPH-4 study included the standard suicide-risk screening tool (the C-SSRS) and didn’t flag a difference between retatrutide and placebo.²

The data so far is limited to trial populations under monitoring, not real-world use.

If you’re considering or taking any weight-loss medication and you notice mood changes, low mood, anxiety, or thoughts of self-harm, contact your GP.

Drug interactions and contraception

Oral contraceptives

Mounjaro’s UK label recommends that women taking the combined oral contraceptive pill switch to a non-oral method, or use a backup method like condoms for four weeks after starting Mounjaro and four weeks after each dose increase.

The reason is that slowed gastric emptying can reduce contraceptive absorption, particularly during dose changes.

Whether retatrutide has the same effect isn’t yet documented in detail, but it slows gastric emptying in the same way, so the issue likely applies.

If you’re on the pill and considering any GLP-1 medication, speak to your GP about contraception options before you start.

Pregnancy and breastfeeding

GLP-1 medications, including retatrutide, aren’t recommended during pregnancy or breastfeeding.

You shouldn’t take GLP-1 weight medications if you’re trying to conceive, are pregnant, or are breastfeeding.

Most clinicians recommend stopping the medication at least two months before trying for a baby.

Other medications taken by mouth

If you take warfarin, thyroid medication, or any medication where the dose is finely tuned, slowed gastric emptying can affect blood levels during dose changes. Your clinician may want to monitor more closely.

Other side effects

Retatrutide trials have also reported the following side effects, though they’re less common:^1,2,3

• Injection site reactions. Redness, mild bruising, or itching at the injection site. Rotating between the abdomen, thigh, and upper arm helps reduce skin irritation.
• Fatigue. Reported across doses, often related to reduced food intake during the stepping-up phase.
• Headache. More common during dose increases and usually settles.
• Decreased appetite. This is part of how the medication works rather than a problem in itself, but at high doses, some people report eating too little. If you’re losing weight too quickly without trying to, your clinician may slow the dose schedule.
• Gallbladder problems. Rare in the trials, but a recognised concern with GLP-1 medications generally, partly because rapid weight loss itself can trigger gallstones. Sudden severe pain in the upper right side of the abdomen needs medical review.
• Pancreatitis. Very rare in the trials and not consistently linked to retatrutide specifically, but a known concern across the GLP-1 family. Severe, persistent abdominal pain that radiates to the back is the classic warning sign.

Thyroid C-cell tumours are mentioned as a warning across GLP-1 medications based on rodent studies. No human cases have been linked to retatrutide in clinical trials so far.¹

How retatrutide compares to Mounjaro and Wegovy

Retatrutide’s side-effect rates are similar to other GLP-1 medications on the most common symptoms, with some differences at the higher doses.^1,2,4

Stomach and gut rates are similar across the three medications at their highest doses.

Retatrutide’s distinguishing features are the larger heart-rate increase and the dysesthesia rate at 12 mg.^1,2,4

Wegovy already has cardiovascular outcomes data through the SELECT trial, which showed a 20% reduction in serious heart events.

Mounjaro’s cardiovascular outcomes trial (SURMOUNT-MMO) is due to be published soon. Retatrutide’s cardiovascular outcomes trial isn’t expected to be published until 2028 at the earliest.

Discontinuation and weight regain

How often people stop the medication

• TRIUMPH-4 (n=445, 68 weeks, obesity with knee osteoarthritis): 18.2% on 12 mg, 12.2% on 9 mg, 4% on placebo²
• TRANSCEND-T2D-1 (n=537, 40 weeks, type 2 diabetes): 5.1% on 12 mg, 4.5% on 9 mg, 0% on placebo³
• Phase 2 (n=338, 48 weeks): 6 to 16% across doses, 1% on placebo¹

For comparison, Wegovy’s STEP-1 trial reported a discontinuation rate of around 7% due to side effects, and Mounjaro’s SURMOUNT-1 reported a similar rate.⁴

Retatrutide’s TRIUMPH-4 figure is higher; TRANSCEND-T2D-1 sits closer to its comparators.

The gap reflects differences in trial duration, population, and what counted as a reason to stop.

Lilly noted that some TRIUMPH-4 dropouts were people who lost more weight than they intended, which would inflate the figure compared with strictly tolerance-driven dropouts.²

In practice, most people tolerate retatrutide once they reach a stable dose. A meaningful minority don’t, and slow dose increases appear to be the most reliable way to reduce that.

What happens if you stop

Retatrutide hasn’t published a formal withdrawal trial, but the same pattern seen with other GLP-1 medications is expected.

In SURMOUNT-4, adults who had lost an average of 20.9% of their starting weight on Mounjaro over 36 weeks, then switched to placebo, regained 14% of their starting weight over the following year, retaining only about a third of their initial loss.⁵

Still, this research shows what happens when you stop the medications suddenly without a gradual decrease in dose (a taper), and with adequate lifestyle support alongside it.

Emerging research suggests that people who come off the medication gradually, with structured habit-change support, are more likely to maintain their weight loss.

What we don’t yet know

• Long-term cardiovascular outcomes. No dedicated cardiovascular outcomes trial has been reported. Whether the heart-rate and irregular-heartbeat findings translate into more or fewer serious heart events over 5 to 10 years isn’t yet known.
• Why dysesthesia happens. The leading hypothesis points to the glucagon component, but high-dose Wegovy has now shown similar effects. Until the underlying cause is confirmed, predicting who will get it is difficult.
• Real-world tolerance. Phase 3 trial discontinuation rates are useful, but real-world data tend to show different patterns once a drug is widely prescribed. Post-approval data won’t exist until retatrutide is approved.
• Safety in less-studied groups. Pregnancy, severe kidney or liver impairment, adults over 75, and people with several health conditions at once are typically under-represented in trials.
• Effects beyond 68 weeks. The longest Phase 3 result published so far covers 68 weeks. Side-effect patterns over multi-year use aren’t yet established.

These gaps are why regulators take the time they do, and why grey-market retatrutide is risky.

Dose, purity, and clinical monitoring all sit outside the oversight that an MHRA-approved medication provides.⁶

When to speak to a healthcare professional

Speak to your GP or a regulated UK clinician if you experience any of the following:

• Nausea or vomiting that lasts more than 24 hours, or that stops you from keeping fluids down
• Persistent or severe abdominal pain, especially if it radiates to your back (a possible sign of pancreatitis)
• Sudden, severe pain in the upper right side of your abdomen (a possible sign of gallstones or gallbladder inflammation)
• Persistent burning, tingling, or unusual skin sensitivity
• Palpitations, a sustained racing heart, dizziness, or chest discomfort
• Yellowing of the skin or eyes, dark urine, or pale stools (possible signs of liver problems)
• Signs of dehydration: dry mouth, low urine output, dizziness on standing, confusion
• Low mood, anxiety, or thoughts of self-harm
• If you bought retatrutide online and notice any new or unexpected symptoms

Retatrutide isn’t currently MHRA-approved.⁶

If you’ve sourced it through unregulated online channels, your GP can’t always tell what dose, purity, or formulation you’re dealing with.

Be open with them about what you’ve taken, when, and any symptoms you’ve noticed.

Frequently asked questions

How long do retatrutide side effects last?

Most stomach and gut side effects (nausea, vomiting, diarrhoea, constipation) appear in the first one to two weeks after a dose increase and settle over four to six weeks once the body adjusts.¹

Heart-rate changes can persist longer but tend to plateau or decline as treatment continues.

Dysesthesia in the trials was usually mild and resolved during ongoing treatment.²

Is retatrutide more dangerous than Mounjaro or Wegovy?

We don’t yet have the long-term data to say definitively.

Stomach and gut rates are similar across the three medications.

Retatrutide’s heart-rate increase is larger, and the dysesthesia rate at 12 mg is higher than what’s been reported for Mounjaro. Wegovy’s new 7.2 mg dose has now flagged similar skin sensations.^2,4

Wegovy and Mounjaro also have cardiovascular outcomes work that retatrutide hasn’t completed yet.

What’s the most common side effect of retatrutide?

Nausea is the most common, affecting up to 60% of people on the highest 12 mg dose in the Phase 2 trial and around 43% in TRIUMPH-4.^1,2

It usually appears during dose increases and improves with continued treatment.

Does retatrutide cause hair loss?

Hair loss isn’t a retatrutide-specific side effect in the published trials.

Significant weight loss from any cause, including diet, surgery, or any GLP-1 medication, can trigger temporary hair shedding (telogen effluvium) because of how the body responds to rapid change.

Hair usually grows back as weight stabilises.¹

What is dysesthesia, and is it permanent?

Dysesthesia is an altered sense of touch, often described as burning, tingling, or unusual sensitivity to the skin.

In the TRIUMPH-4 trial, most cases were mild and resolved during ongoing treatment.²

What happens after stopping the medication long-term isn’t yet well studied.

Can retatrutide cause heart problems?

Retatrutide raises resting heart rate by around 6.7 bpm at 12 mg in the Phase 2 trial.¹

Irregular heartbeats were reported in 2 to 11% of people on retatrutide compared with around 2% on placebo, none classified as serious so far.^1,2

No increase in serious heart events (heart attack, stroke) has been reported, but a dedicated cardiovascular outcomes trial is still pending.

Will retatrutide affect oral contraception?

Mounjaro’s UK label recommends that women on the combined oral contraceptive pill switch to a non-oral method or use backup contraception for four weeks after starting and four weeks after each dose increase.

Whether retatrutide has the same effect isn’t yet documented in detail, but it slows gastric emptying in the same way, so the issue likely applies.

Speak to your GP about contraception options before starting any GLP-1 medication.

Does retatrutide cause muscle loss?

Some of the weight you lose on any GLP-1 medication is muscle, not fat.

In the published trials, around a quarter of total weight loss has come from lean tissue.

The two things that protect muscle while you lose weight are getting enough protein (1.2 to 1.6 grams per kg of body weight per day) and resistance training a couple of times a week.

How can I reduce the side effects of retatrutide?

The most reliable approach is to increase the dose slowly.

Lilly’s Phase 2 data showed that starting at 2 mg rather than 4 mg reduced nausea and vomiting during the stepping-up phase.¹

Beyond that, smaller portions, lean protein, lighter meals after injection, good hydration, and movement after meals all help.

Is it safe to buy retatrutide online?

No. Retatrutide isn’t legally available in the UK as of May 2026, and online ‘research chemical’ listings sit outside MHRA medicines regulation.

The MHRA disrupted UK facilities producing counterfeit GLP-1 medicines in February 2026.⁶

Purity, dose accuracy, and formulation cannot be verified for these products.

If you’ve already taken retatrutide bought online, speak to your GP. For more, read our guide on why retatrutide isn’t safe to buy online.

When will retatrutide be approved in the UK?

The realistic timeline puts MHRA approval at late 2027 to mid 2028, with NHS access through NICE technology appraisal arriving in 2029 at the earliest.²

For more details, read our guide on when retatrutide might be available on the NHS.

Take home message

Retatrutide’s side effects fall into three main groups: stomach and gut symptoms during dose increases, a heart-rate increase larger than other GLP-1 medications, and a skin sensation (dysesthesia) that emerged at higher doses in Phase 3.

Most are manageable with slow dose increases and clinical supervision, and most settle once people reach a stable dose.

Some of the weight lost on retatrutide is muscle, not fat. Losing weight slowly, eating enough protein and resistance training help protect against that.

The longer-term safety profile of retatrutide is unclear.

There’s no completed cardiovascular outcomes trial for retatrutide yet, the cause of dysesthesia isn’t fully understood, and real-world data isn’t available because the drug isn’t approved.

These gaps are why regulators take the time they do, and why grey-market retatrutide is unsafe.

Dose, purity, and clinical monitoring all sit outside the oversight that an MHRA-approved medication provides.

For now, MHRA-approved options like Mounjaro and Wegovy remain the starting point for most adults in the UK considering medication-supported weight loss.

Second Nature’s medication programme combines Mounjaro with structured support from registered dietitians, including the balanced plate model (half vegetables, quarter protein, quarter complex carbohydrates such as wholegrains and beans, plus a serving of fat) and habit-building tools.

Our peer-reviewed JMIR study of the GLP-1RA-supported programme reported an average weight loss of 19.1% at 12 months among active subscribers, with 77.7% achieving at least 10% weight loss.⁷

References

1. Jastreboff, A.M. et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. New England Journal of Medicine, 389(6), 514-526.
2. Eli Lilly and Company. (2025, December 11). Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial (TRIUMPH-4 press release).
3. Eli Lilly and Company. (2026, March). Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for type 2 diabetes (TRANSCEND-T2D-1 press release).
4. Jastreboff, A.M. et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 387(3), 205-216.
5. Aronne, L.J. et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38-48.
6. Medicines and Healthcare products Regulatory Agency. (2026, February 25). MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight-loss medicines.
7. Richards, R., Whitman, M., Wren, G., Campion, P. (2025). A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation. JMIR Formative Research, 9(1), e72577.